Navigation Links
PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
Date:8/5/2010

, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents that expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-Looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
  • The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
  • Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
  • The outcome of pending litigation or disputes; and
  • The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.
  • <
    '/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
2. Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life
3. Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
4. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
5. Chinese Biopharmaceutical Association Holds 15th Annual Conference in Rockville, MD, June 12 - 13
6. IntraLinks Announces Partnership With SAFE-BioPharma; Will Provide Digital Identity Capabilities With its Life Sciences Solutions
7. PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010
8. PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
9. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
10. Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges
11. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Invetech ... development, custom automation, and contract manufacturing, and  NanoCellect ... flow cytometry and cell sorting technology for life ... a novel flow cytometry platform. Headquartered ... Biomedical has developed a microchip-based cell sorting technology. ...
(Date:4/21/2015)... , April 21, 2015  scPharmaceuticals, Inc., ... pharmaceutical products for subcutaneous delivery, announced today ... of its investigational proprietary drug product, Furosemide ... associated with congestive heart failure. ... developing a proprietary patch pump.  The patch ...
(Date:4/21/2015)... Cleveleys (UK) (PRWEB) April 21, 2015 ... technology and its clinical applications will be ... Participants include engineers, scientists, regulators and clinicians ... The meeting is sponsored by Invibio Biomaterial ... polymer-based biomaterials, a specialist in manufacturing and ...
(Date:4/20/2015)... and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) (DelMar and the Company), ... proven cancer therapies in new orphan drug indications, ... 106th Annual Meeting of the American Association for ... potential for its lead product candidate VAL-083 ...
Breaking Biology Technology:NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5
... will hold the $14 million clinical training programs administrative ... of Wisconsin-Madison intends to train more clinical researchers, whose ... science, with the help of a $14 million, five-year ... , ,Molly Carnes, a professor with appointments in the ...
... UW-Stout gets USDA grant for manufacturing training ETC announces ... in third quarter QRG Bioscience to move to Research ... , Home Health United signs deal with SBC ... a three-year deal with communications firm SBC . SBC will implement ...
... 21st Century Act, commonly called Check 21, two Wisconsin ... imaging. , ,Check 21, which will come into effect ... of the payments system by legalizing the use of ... documents. Using the substitute check, banks are permitted to ...
Cached Biology Technology:$14 million grant to drive clinical research at UW 2Tech Digest: whats moving in the Midwest 2Tech Digest: whats moving in the Midwest 3Wisconsin firms make acquisitions for Check 21 readiness 2
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... are often touted as one method to help decrease society,s addiction ... to be done before fuel cells will be ready for mass ... for emergencies. U of C chemists Jeff Hurd and George ... cell towards a higher level of design. They have discovered a ...
... Scientists are developing new scaffolding technology which could ... and cartilage using 3D spaghetti-like structures. Their research is ... highlights magazine of the Biotechnology and Biological Sciences Research ... by scientists from the University of Bristol, using proteins ...
... clinical-stage biopharmaceutical company developing a new class of drugs ... data from its recently completed Phase 2b clinical trial ... with major depressive disorder, or MDD, who did not ... citalopram hydrobromide. In the trial, the add-on TC-5214 ...
Cached Biology News:U of C chemists discover recipe to design a better type of fuel cell 2'Spaghetti' scaffolding could help grow skin in labs 2Targacept's P.2b depression study succeeds: 6-point difference on HAM-D 2Targacept's P.2b depression study succeeds: 6-point difference on HAM-D 3
... AP Conjugate Stabilizer is an aqueous ... protein and other non-toxic stabilizing chemicals ... pH 5.5 6.5. This ... methylisothiazolone and 0.02% bromonitrodioxane as a ...
MAb to Myoglobin Cardiac...
... binding is a problem in your ... immobilized NeutrAvidin products as superior alternatives ... a modified avidin derivative that combines ... biotin-binding protein with exceptionally low nonspecific ...
Request Info...
Biology Products: